Brief: 4Dmt Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For 4D-150 Genetic Medicine
21/12/2023 14:33
Dec 21 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4DMT RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY
(RMAT)
DESIGNATION FOR 4D-150 GENETIC MEDICINE FOR INTRAVITREAL
TREATMENT OF WET AMD, THE FIRST RMAT DESIGNATION IN WET AMD
* 4D MOLECULAR THERAPEUTICS INC-WORKING WITH FDA AND EMA ON
PRELIMINARY PHASE 3 CLINICAL TRIAL PLANS AND EXPECTS TO PROVIDE
UPDATE IN FEB 2024
Source text for Eikon: ID:nGNX5d84v7
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings